Clinical Trials Logo

ASXL1 Gene Mutation clinical trials

View clinical trials related to ASXL1 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT03303950 Terminated - Anemia Clinical Trials

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Start date: March 30, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving busulfan and fludarabine before and cyclophosphamide after donor stem cell may work better in treating participants with multiple myeloma or myelofibrosis.

NCT ID: NCT03303716 Recruiting - ASXL1 Gene Mutation Clinical Trials

ASXL-Related Disorders Registry

Start date: September 20, 2017
Phase:
Study type: Observational [Patient Registry]

A registry focused on the natural history, management and treatment of patients with Bohring-Opitz Syndrome (ASXL1), Shashi-Pena Syndrome (ASXL2) and Bainbridge-Ropers Syndrome (ASXL3).